TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04366349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melrilimab (GSK3772847) 70 milligram (mg)
Description: melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melrilimab (GSK3772847) 140 milligram (mg)
Description: Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
Study: NCT00537134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization, coiling
Description: Endovascular embolization with platinum coils
Study: NCT04459013

Intervention type: OTHER
Intervention: Salivary samples
Description: The salivary samples will be collected at 5 defined times
Study: NCT02952378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumins
Description: Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumins
Description: Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
Study: NCT04037618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-EYP001a
Description: Oral drinking suspension
Study: NCT03420170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Exercise Integrated Education
Description: Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)
Study: NCT03269526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR BATs after standard of care chemo
Description: Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
Study: NCT03957551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
Study: NCT03626727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate Oral Solution [Xyrem]
Description: Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
Study: NCT02620839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00609102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-aceylcysteine
Description: 450 mgm BID
Study: NCT00712751

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline.

Intervention type: BEHAVIORAL
Intervention: CSI-SH- Cancer Survivorship Intervention
Description: This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
Study: NCT03023449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled Nitric Oxide gas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Inhaled Nitric Oxide gas
Study: NCT04710901

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: uTECH + YMHP
Description: uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YMHP
Description: YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: uTECH
Description: uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention.
Study: NCT04208919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived DCreg
Description: Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
Study: NCT03935984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: Treatment with calcitonin to lower high calcium levels prior to reimaging exam
Study: NCT03355976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg flat dose every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg flat dose every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg flat dose every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg flat dose every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg every 6 weeks
Study: NCT03550027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX
Description: Positioning of drainage PleurX

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleurocath
Description: Positioning of drainage Pleurocath
Study: NCT04065139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
Study: NCT02546167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Study: NCT04052334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL
Description: Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
Study: NCT04033796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25,000 IU
Description: Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 IU
Description: Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (administered orally every two months) supplementation control group.
Study: NCT01088568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the implantation of toric implantable collamer lens
Description: perform the implantation of toric implantable collamer lens for both eyes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: customized laser-assisted in situ keratomileusis
Description: perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
Study: NCT04236427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Wan
Description: Angong Niuhuang Wan 3g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angong Niuhuang Wan Placebo
Description: Angong Niuhuang Wan Placebo 3g
Study: NCT02856412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veterans Group Exercise (VGX)
Description: Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management and Recovery
Description: Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
Study: NCT03406884

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: c-kit+ cells
Description: The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: c-kit+ cells
Description: The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
Study: NCT04507412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: perioperatively 9 mg i.v subministration
Study: NCT03968679

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unilateral elective nodal irradiation
Description: After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
Study: NCT02360579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
Study: NCT03420170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
Study: NCT05023421

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03757091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy
Description: Undergo video laryngoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Undergo flexible scope intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: Undergo flexible scope intubation
Study: NCT03537963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Stepped-care Intervention
Description: Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
Study: NCT02791425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface (BCI) device
Description: A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication picture board
Description: The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
Study: NCT03537963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Stepped-care Intervention
Description: Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control Condition
Description: General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interviews
Description: To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
Study: NCT02962401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment
Study: NCT01679288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (Trademark:VScan; Manufacturer:General Electrics)
Description: Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
Study: NCT04505059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precision cardiac anesthesia
Description: Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiac anesthesia
Description: The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
Study: NCT02326623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction
Description: distraction using an iPad with a selection of child-appropriate games

Intervention type: OTHER
Group type: OTHER
Intervention: topical anesthetic cream
Description: standard care is to use a topical anesthetic cream at the site of planning IV access
Study: NCT03323892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: second masturbation
Description: Husbands will be asked to produce a second sperm sample in the masturbatorium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second masturbation
Description: Husbands will be asked to produce a second sperm sample in the masturbatorium